loading
前日終値:
$12.20
開ける:
$12.3
24時間の取引高:
787.61K
Relative Volume:
0.79
時価総額:
$710.99M
収益:
$88.24M
当期純損益:
$-160.90M
株価収益率:
-4.8307
EPS:
-2.6642
ネットキャッシュフロー:
$-129.35M
1週間 パフォーマンス:
-3.45%
1か月 パフォーマンス:
-6.47%
6か月 パフォーマンス:
+27.93%
1年 パフォーマンス:
+27.55%
1日の値動き範囲:
Value
$0.00
$0.00
1週間の範囲:
Value
$11.99
$13.47
52週間の値動き範囲:
Value
$6.96
$16.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name
名前
4 D Molecular Therapeutics Inc
Name
セクター
Healthcare (1051)
Name
電話
(510) 505-2680
Name
住所
5858 HORTON STREET #455, EMERYVILLE
Name
職員
196
Name
Twitter
Name
次回の収益日
2026-11-09
Name
最新のSEC提出書
Name
FDMT's Discussions on Twitter

Compare FDMT vs VRTX, MRNA, REGN, ARGX, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
FDMT icon
FDMT
4 D Molecular Therapeutics Inc
12.87 710.99M 88.24M -160.90M -129.35M -2.6642
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
508.75 128.95B 12.34B 4.34B 3.71B 16.87
MRNA icon
MRNA
Moderna Inc
236.50 94.42B 2.23B -3.19B -1.60B -8.1462
REGN icon
REGN
Regeneron Pharmaceuticals Inc
796.34 81.99B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
846.27 53.22B 4.16B 1.29B 734.26M 19.58
ONC icon
ONC
Beone Medicines Ltd Adr
374.08 42.32B 5.76B 514.49M 1.10B 4.4813

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-09-14 アップグレード Cantor Fitzgerald Neutral → Overweight
2026-07-31 開始されました B. Riley Securities Buy
2026-01-28 再開されました Barclays Overweight
2025-11-07 アップグレード Morgan Stanley Underweight → Equal-Weight
2025-01-13 ダウングレード BMO Capital Markets Outperform → Market Perform
2024-11-21 開始されました Morgan Stanley Underweight
2024-09-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2024-04-15 開始されました Barclays Overweight
2024-02-07 再開されました Goldman Buy
2023-10-26 開始されました RBC Capital Mkts Outperform
2023-10-24 開始されました Cantor Fitzgerald Overweight
2023-10-18 アップグレード Leerink Partners Market Perform → Outperform
2023-07-05 開始されました Chardan Capital Markets Buy
2023-01-30 開始されました BMO Capital Markets Outperform
2022-11-18 開始されました H.C. Wainwright Buy
2022-11-15 アップグレード Goldman Neutral → Buy
2022-08-12 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-06-22 開始されました Jefferies Buy
2022-01-04 開始されました SVB Leerink Outperform
2021-01-05 開始されました BofA Securities Buy
2021-01-05 開始されました Evercore ISI Outperform
2021-01-05 開始されました Goldman Neutral
すべてを表示

4 D Molecular Therapeutics Inc (FDMT) 最新ニュース

pulisher
Oct 08, 2026

Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com India

Oct 08, 2026
pulisher
Oct 07, 2026

Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com Nigeria

Oct 07, 2026
pulisher
Oct 07, 2026

4D molecular therapeutics CEO David Kirn sells $753k in company stock - Investing.com Nigeria

Oct 07, 2026
pulisher
Oct 07, 2026

Form 4 4D Molecular Therapeutics Inc For: 7 October By Investing.com - Investing.com UK

Oct 07, 2026
pulisher
Oct 07, 2026

4D molecular therapeutics CEO David Kirn sells $753k in company stock - Investing.com India

Oct 07, 2026
pulisher
Oct 07, 2026

CEO David Kirn sells 58,061 and 272 shares of 4D Molecular Therapeutics (FDMT) under a trading plan. - Stock Titan

Oct 07, 2026
pulisher
Oct 05, 2026

4D Molecular Therapeutics Officer David Kirn Files Form 144 for Sale of 58,333 Shares - Kalkine Media

Oct 05, 2026
pulisher
Oct 05, 2026

Officer David Kirn plans to sell 58,333 shares of 4D Molecular Therapeutics (FDMT). - Stock Titan

Oct 05, 2026
pulisher
Sep 22, 2026

Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock By Investing.com - Investing.com Nigeria

Sep 22, 2026
pulisher
Sep 22, 2026

Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com Nigeria

Sep 22, 2026
pulisher
Sep 22, 2026

Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com India

Sep 22, 2026
pulisher
Sep 22, 2026

Form 4 4D Molecular Therapeutics Inc For: 22 September By Investing.com - Investing.com UK

Sep 22, 2026
pulisher
Sep 22, 2026

Scott Bizily sells $22,317 of 4D Molecular Therapeutics stock - Investing.com

Sep 22, 2026
pulisher
Sep 22, 2026

4D Molecular (FDMT) legal chief exercises options, then sells 1,635 shares - Stock Titan

Sep 22, 2026
pulisher
Sep 21, 2026

4D Molecular Therapeutics (Nasdaq:FDMT)Stock Analysis - Simply Wall Street

Sep 21, 2026
pulisher
Sep 16, 2026

4D molecular therapeutics CEO Kirn sells $811,003 in stock - Investing.com

Sep 16, 2026
pulisher
Sep 16, 2026

4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com Canada

Sep 16, 2026
pulisher
Sep 16, 2026

4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan - Stock Titan

Sep 16, 2026
pulisher
Sep 16, 2026

4D Molecular Therapeutics Insider Sold Shares Worth $811,004, According to a Recent SEC Filing - Yahoo Finance

Sep 16, 2026
pulisher
Sep 16, 2026

4D molecular therapeutics CEO Kirn sells $811,003 in stock By Investing.com - Investing.com UK

Sep 16, 2026
pulisher
Sep 14, 2026

Insider at 4D Molecular (NASDAQ: FDMT) plans new stock sale after recent trades - Stock Titan

Sep 14, 2026
pulisher
Sep 11, 2026

4D Molecular Therapeutics Grants RSUs to Seven New Non-Executive Employees - quiverquant.com

Sep 11, 2026
pulisher
Sep 11, 2026

Seven new employees get 96,000 stock units from 4DMT - stocktitan.net

Sep 11, 2026
pulisher
Sep 11, 2026

4DMT Announces New Employment Inducement Grants - GlobeNewswire

Sep 11, 2026
pulisher
Sep 10, 2026

FDMT: Phase III data for 4D-150 in wet AMD and DME expected next year, targeting major treatment shifts - TradingView

Sep 10, 2026
pulisher
Sep 10, 2026

FDMT: 4D-150 targets a paradigm shift in wet AMD with major phase III data expected next year - TradingView

Sep 10, 2026
pulisher
Sep 04, 2026

Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com Nigeria

Sep 04, 2026
pulisher
Sep 04, 2026

Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 By Investing.com - Investing.com India

Sep 04, 2026
pulisher
Sep 04, 2026

Scott Bizily, 4D Molecular Therapeutics chief legal officer, sells $8,176 - Investing.com

Sep 04, 2026
pulisher
Sep 03, 2026

4D Molecular Therapeutics (NASDAQ: FDMT) legal chief trades 584 shares at $14 - Stock Titan

Sep 03, 2026
pulisher
Sep 03, 2026

4D Molecular Therapeutics Chief Legal Officer Scott Bizily disposes of 584 common shares for $8,176 - Bitget

Sep 03, 2026
pulisher
Aug 21, 2026

4D Molecular Therapeutics (NASDAQ: FDMT) CEO sells 69K shares in preset plan - Stock Titan

Aug 21, 2026
pulisher
Aug 21, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7%Here's What Happened - MarketBeat

Aug 21, 2026
pulisher
Aug 21, 2026

4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DME - Bitget

Aug 21, 2026
pulisher
Aug 19, 2026

4D (FDMT) Watch: Advances 13.86% to $16.76; Boundary Watch: Price Remains Between $15.92 Support and $17.60 Resistance in Latest TradingSMA Signal - vinanet.vn

Aug 19, 2026
pulisher
Aug 19, 2026

David Kirn plans $1.16M 4D Molecular (NASDAQ: FDMT) stock sale - Stock Titan

Aug 19, 2026
pulisher
Aug 18, 2026

HC Wainwright Has Bullish Forecast for FDMT FY2027 Earnings - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

146,185 Shares in 4D Molecular Therapeutics, Inc. $FDMT Bought by Perigon Wealth Management LLC - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com Canada

Aug 18, 2026
pulisher
Aug 18, 2026

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock - Investing.com

Aug 18, 2026
pulisher
Aug 18, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Sets New 12-Month HighTime to Buy? - MarketBeat

Aug 18, 2026
pulisher
Aug 18, 2026

4D Molecular Therapeutics CLO Scott Bizily sells $39,567 in stock By Investing.com - Investing.com India

Aug 18, 2026
pulisher
Aug 17, 2026

4D Molecular Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs

Aug 17, 2026
pulisher
Aug 17, 2026

4D Molecular Therapeutics CLO Scott Bizily Executes Stock Option Exercises and Sales Under 10b5-1 Plan - Kalkine Media

Aug 17, 2026
pulisher
Aug 17, 2026

Scott Bizily Sells 1,635 Shares of 4D Molecular Therapeutics (NASDAQ:FDMT) Stock - MarketBeat

Aug 17, 2026
pulisher
Aug 17, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares of Stock - MarketBeat

Aug 17, 2026
pulisher
Aug 17, 2026

4D Molecular Therapeutics (NASDAQ: FDMT) legal chief sells 3,270 shares - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

Scott Bizily plans new 4D Molecular (NASDAQ: FDMT) sale after 10b5-1 stock trades - Stock Titan

Aug 17, 2026
pulisher
Aug 17, 2026

4D Molecular Therapeutics (NASDAQ:FDMT) Shares Up 10%Time to Buy? - MarketBeat

Aug 17, 2026

4 D Molecular Therapeutics Inc (FDMT) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

4 D Molecular Therapeutics Inc (FDMT) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
David Kirn
Officer
Oct 05 '26
Proposed Sale
12.92
58,333
753,662
0
Bizily Scott
Chief Legal Officer
Sep 16 '26
Sale
13.65
1,635
22,318
8,617
Bizily Scott
Chief Legal Officer
Sep 16 '26
Option Exercise
4.14
1,635
6,769
10,252
Kirn David
See Remarks
Sep 14 '26
Sale
13.90
58,333
811,004
767,486
David Kirn
Officer
Sep 14 '26
Proposed Sale
13.76
58,333
802,662
0
Bizily Scott
Chief Legal Officer
Sep 01 '26
Option Exercise
6.49
584
3,790
9,201
Bizily Scott
Chief Legal Officer
Sep 01 '26
Sale
14.00
584
8,176
8,617
Kirn David
See Remarks
Aug 19 '26
Sale
15.75
69,076
1,088,273
825,819
David Kirn
Officer
Aug 19 '26
Proposed Sale
16.76
69,076
1,157,714
0
Kirn David
See Remarks
Aug 19 '26
Option Exercise
4.14
50,000
207,000
894,895
$6.97
price down icon 0.43%
$8.68
price up icon 2.00%
$1.65
price up icon 3.12%
$4.73
price up icon 3.96%
IVA IVA
$3.11
price up icon 8.36%
$4.68
price down icon 0.43%
大文字化:     |  ボリューム (24 時間):